ZR-75-30 Cells

ZR-75-30 is a human breast cancer cell line derived from a ductal carcinoma. Genomic profiling studies have shown that ZR-75-30 harbors amplification of the ERBB2/HER2 gene, a key driver in a subset of breast cancers. This amplification results in elevated HER2 protein expression, which has been linked to increased proliferation and resistance to certain therapies. Additionally, ZR-75-30 exhibits alterations in the epidermal growth factor receptor (EGFR) signaling pathway, including gains of EGFR-related genes, suggesting that the cell line may be useful in studying HER2-targeted therapies and their resistance mechanisms. Transcriptomic analyses have placed ZR-75-30 within the luminal subtype of breast cancer, supporting its relevance for studying endocrine therapy responses. The cell line has been included in studies evaluating precision medicine approaches, where molecular profiling has helped predict responses to targeted treatments. Given its molecular characteristics, ZR-75-30 is widely used as a preclinical model for evaluating hormone receptor-targeted therapies and HER2 inhibitors, making it a valuable tool in breast cancer research.